Which is more effective: entrectinib/Luo Shengquan or larotrectinib?

Entrectinib(Entrectinib) and larotrectinib (Larotrectinib) are both TRK inhibitor targeted drugs and are mainly used in patients with non-small cell lung cancer and solid tumors carrying NTRK gene fusions. The research and development ideas of the two are similar. They both inhibit the growth and spread of tumor cells by blocking the abnormal signaling of neurotrophic factor receptor tyrosine kinase (TRK). However, there are differences between the two in terms of clinical application scope, side effect spectrum and pharmacological properties.

The outstanding feature of larotrectinib is its strong specificity. It almost exclusively targetsNTRK fusion-positive tumors. The drug design is relatively "pure" and suitable for patients with clear such genetic changes. Its side effect spectrum is relatively mild and well tolerated by most patients, so it also has application advantages in pediatrics and young patients.

Enrectinib is considered a "multi-target" drug. In addition to inhibiting TRK, it can also act on targets such as ROS1 and ALK, so it has been more widely used in the field of common tumors such as lung cancer. It can cover a more complex molecular spectrum, especially showing strong activity against ROS1-positive non-small cell lung cancer, which makes its scope of application broader than larotrectinib. At the same time, due to its wider scope of action, the side effects spectrum of entrectinib is also slightly complex, including fatigue, gastrointestinal discomfort, taste changes, etc., which requires closer monitoring and management.

From the perspective of effectiveness, larotrectinib has a higher response rate and longer duration inNTRK fusion-positive patients, and is suitable for precise people with clear gene targets. Entrectinib shows additional value when taking into account driver mutations such as NTRK and ROS1, especially for patients with lung cancer and some rare tumors. Therefore, the two cannot be judged purely based on "who is more effective", but should be selected based on the patient's genetic characteristics, comorbidities, and drug tolerance.

Reference materials:https://www.roche.com/products/rozlytrek